Skip to content

Effect of loxenatide vs. canagliflozin in patients with type 2 diabetes mellitus and sarcopenia: A randomized, open, controlled and single-site clinical trail

Effect of loxenatide vs. canagliflozin in patients with type 2 diabetes mellitus and sarcopenia: A randomized, open, controlled and single-site clinical trail

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074382
Enrollment
Unknown
Registered
2023-08-04
Start date
2023-08-05
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenia

Interventions

loxenatide group:Cargliflozin + Metformin
canagliflozin group:Losenatide+Metformin

Sponsors

Nanjing Drum Towre Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) 40years old=age=75years old, regardless of gender; (2) T2DM patients with poor blood glucose control after metformin (=1000mg/d) monotherapy for 2 months or metformin (=1000mg/d) combined with other hypoglycemic drugs (excluding GLP-1 receptor agonists and SGLT-2 inhibitors); (3)7%=HbA1c=11 % (4)BMI=20kg/m2 (5) Myopenia exists, meeting the first and second and/or third of the following: 1) The limb muscle mass after height correction is less than 7.0 kg/m2 for males and 5.4 kg/m2 for females; 2) Grip strength: male < 28kg, female < 18kg; 3) Walk at a normal speed of 6m, and the step speed is less than 1m/s. Or subclinical myopenia: only the first item above is met. (6) The limbs have no disability or related diseases, and can be tested for grip strength and walking speed; (7) Agree to sign the informed consent form. T2DM is defined as meeting the diagnostic criteria of the American Diabetes Association (ADA) for T2DM in 2019.

Exclusion criteria

Exclusion criteria: (1) Have a known or suspected history of allergy to the test drug or similar drugs; (2) Moderate and severe renal insufficiency is defined as eGFR 2.5 times the upper limit of normal reference value; (3) Complicated with acute cardiovascular and cerebrovascular diseases, mental diseases, thyroid diseases, malignant tumors, pancreatitis, severe gastrointestinal diseases, acute infections or the use of hormone drugs; (4) Bad smoking and drinking habits; (5) Receive other test drugs at present or within 3 months before participating in this project; (6) Pregnancy plan during pregnancy, lactation and near future; (7) Any situation judged by the investigator that affects the enrollment.

Design outcomes

Primary

MeasureTime frame
muscle mass;muscle strength;pace;urinalysis;

Secondary

MeasureTime frame
FBG;2h PG;inbody;HbA1c;weight;blood pressure;Fibro Touch;

Countries

Jiangsu

Contacts

Public ContactFeng wenhuan

Nanjing Drum Towre Hospital

fengwh501@163.com+86 137 7084 0866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026